

with a  
**biotech  
mindset**

»  
No competing  
internal pipeline  
Exclusively sourcing  
through **external  
innovation**

»  
Direct leadership  
decision-making for  
all programs  
**accelerates  
execution**

»  
Talents attracted  
from Pharma, Biotech  
and academia, to  
drive shared success  
through **creative  
collaborations**

»»»» OUR GLOBAL PARTNERING & EXTERNAL INNOVATION TEAM

- Oncology
- Rare Disease
- Neuroscience



**Philippe Lopes-Fernandes**  
EVP, Chief Business Officer  
philippe.lopes-fernandes@ipsen.com



**David Jenkins**  
SVP, Head of Research & External Innovation  
david.jenkins@ipsen.com

Rare Disease & Neuroscience  
Global Partnering team



**Lori Badura**  
VP, Head of Global Rare Disease  
& Neuroscience Partnering  
lori.badura@ipsen.com



**Marine Beurdeley**  
Sr. Dir., Global Partnering  
marine.beurdeley@ipsen.com



**Edouard Caram**  
Sr. Dir., Global Partnering  
edouard.caram@ipsen.com

Late-Stage Global Partnering Team



**Jean-Patrick Hennebelle**  
Sr. VP, Head of Global Late-Stage Partnering  
jean-patrick.hennebelle@ipsen.com



**Romain Vitte**  
Sr. Dir., Global Partnering  
romain.vitte@ipsen.com



**Jean-Baptiste de Peretti**  
Sr. Mgr., Global Partnering  
jean-baptiste.de.peretti@ipsen.com

Oncology Global Partnering Team



**Nick Gagnon**  
VP, Head of Oncology Global Partnering  
nick.gagnon@ipsen.com



**Jordan Gass**  
Sr. Dir., Global Partnering  
jordan.gass@ipsen.com



**Madee Gooriah**  
Sr. Dir., Global Partnering  
madee.gooriah@ipsen.com



**Masha Kurbatova**  
Sr. Dir., Global Partnering  
masha.kurbatova@ipsen.com



**Aurore Bernier Gruson**  
Dir., Global Partnering  
aurore.bernier.gruson@ipsen.com

External Innovation Team



**Anuradha Connor**  
VP, Head of Oncology  
External Innovation  
anuradha.connor@ipsen.com



**Clément Gautier**  
Sr. Dir., Head of Neuroscience &  
Rare Disease External Innovation  
clement.gautier@ipsen.com



**Srimoyee Ghosh**  
Sr. Dir., External Innovation  
srimoyee.ghosh@ipsen.com



**Chris Hupp**  
Sr. Dir., External Innovation  
christopher.hupp@ipsen.com



**Jon Travers**  
Sr. Dir., External Innovation  
jon.travers@ipsen.com



**Mike Burbridge**  
Sr. Dir., External Innovation  
mike.burbridge@ipsen.com



**Kalyan Chakravarthy**  
Assoc. Dir., External Innovation  
kalyan.chakravarthy@ipsen.com



**Guillaume Harmange**  
Principal Scientist, External Innovation  
guillaume.harmange@ipsen.com



**Matthew Beard**  
Sr. Dir., External Innovation  
matthew.beard@ipsen.com



**Savitri Mandapati**  
Assoc. Dir., External Innovation  
savitri.mandapati@ipsen.com



**Chris Vlahos**  
Sr. Dir., External Innovation  
chris.vlahos@ipsen.com



**Florence Dal Degan**  
Sr. Dir., External Innovation  
florence.dal.degan@ipsen.com



**Shira Landskroner-Eiger**  
Dir., External Innovation  
shira.landskroner-eiger@ipsen.com

Alliance Management Team



**Naomi Binoche**  
VP, Head of Alliance Management  
naomi.binoche@ipsen.com



**Eric Ferrandis**  
VP, Strategic Alliances  
eric.ferrandis@ipsen.com



**Sarah Desi**  
Sr. Dir., Strategic Alliances  
sarah.desi@ipsen.com



**Guillaume Gimonet**  
Sr. Dir., Strategic Alliances  
guillaume.gimonet@ipsen.com



**Tammi Reza**  
Sr. Dir., Strategic Alliances  
tammi.reza@ipsen.com



**Delphine Vignaud**  
Sr. Dir., Strategic Alliances  
delphine.vignaud@ipsen.com



**Meryem Nadifi**  
Dir., Strategic Alliances  
meryem.nadifi@ipsen.com

Please contact the appropriate team member or email [bus.devpt@ipsen.com](mailto:bus.devpt@ipsen.com)



Together  
with Ipsen



**Global**  
With the power to maximize the  
potential of your innovations



**Right-Sized**  
With the proven ability to develop and  
bring your innovations to patients



**Focused**  
In 3 core areas: Oncology,  
Rare Disease, Neuroscience



**Relationship Driven**  
Showing the same devotion to the  
success of your asset as you do

WE HAVE THE TENACITY TO CARRY YOUR INNOVATIONS FORWARD

2023 company turnover of >€3bn & 7 medicines with potential sales of >€500m by 2027

Track record maximizing every asset worldwide across multiple indications

a global biopharma company...



Solid financial execution generating €5bn cumulative firepower by 2027<sup>1</sup>



<sup>1</sup> Based on net debt at 2.0x EBITDA and excluding sale of any assets

GROWING AND PUSHING BOUNDARIES

Global leader delivering >€3bn sales in 2023 with growth across all regions



<sup>2</sup> Based on full-year 2023 total sales. Europe is defined in this presentation as the E.U., the U.K., Iceland, Liechtenstein, Norway and Switzerland.

GREAT PARTNERSHIPS CREATE GREAT POSSIBILITIES

Bringing new acquisitions, licenses & partnerships into our portfolio



### Future expansion in 3 core areas

- Oncology**
  - Solid tumors & hematology
  - Precision medicine approaches
  - BIC/FIC with strong science and meaningful differentiation
  - Smaller patient segments attractive for mid-sized companies
- Rare Disease**
  - High unmet needs in underserved rare diseases
  - Drive liver & bone franchises; expand to new disease areas
  - Good fit for clinical development & go-to-market model
- Neuroscience**
  - Rare neuroscience
  - Expand beyond neurotoxins in non-rare to adjacent areas
  - Strong innovation & scientific advances